IRIS
TONIUTTO, Pierluigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.047
AS - Asia 7.007
EU - Europa 4.681
SA - Sud America 1.260
AF - Africa 160
Continente sconosciuto - Info sul continente non disponibili 22
OC - Oceania 5
Totale 30.182
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.767
SG - Singapore 3.485
CN - Cina 1.348
UA - Ucraina 1.060
BR - Brasile 986
DE - Germania 819
HK - Hong Kong 700
IT - Italia 502
VN - Vietnam 476
FR - Francia 444
FI - Finlandia 420
RU - Federazione Russa 359
SE - Svezia 327
TR - Turchia 245
IE - Irlanda 242
GB - Regno Unito 197
IN - India 166
CA - Canada 148
AR - Argentina 107
KR - Corea 101
BD - Bangladesh 88
MX - Messico 83
IQ - Iraq 65
PL - Polonia 57
ZA - Sudafrica 47
BE - Belgio 46
EC - Ecuador 43
JP - Giappone 43
IR - Iran 39
PK - Pakistan 39
ID - Indonesia 37
AT - Austria 36
CO - Colombia 36
ES - Italia 35
NL - Olanda 33
UZ - Uzbekistan 24
VE - Venezuela 24
PH - Filippine 23
PY - Paraguay 23
MA - Marocco 22
SA - Arabia Saudita 20
EU - Europa 19
CL - Cile 18
KE - Kenya 16
CZ - Repubblica Ceca 15
LT - Lituania 13
AE - Emirati Arabi Uniti 12
DZ - Algeria 11
AZ - Azerbaigian 10
CH - Svizzera 10
ET - Etiopia 10
PE - Perù 10
EG - Egitto 9
TG - Togo 9
TN - Tunisia 9
GR - Grecia 8
AL - Albania 7
DO - Repubblica Dominicana 7
JO - Giordania 7
NP - Nepal 7
AO - Angola 6
BO - Bolivia 6
HN - Honduras 6
MY - Malesia 6
BH - Bahrain 5
DK - Danimarca 5
EE - Estonia 5
HU - Ungheria 5
JM - Giamaica 5
LB - Libano 5
NI - Nicaragua 5
PA - Panama 5
PS - Palestinian Territory 5
SN - Senegal 5
TW - Taiwan 5
BB - Barbados 4
HR - Croazia 4
KG - Kirghizistan 4
KW - Kuwait 4
LK - Sri Lanka 4
LV - Lettonia 4
OM - Oman 4
QA - Qatar 4
RO - Romania 4
UY - Uruguay 4
AM - Armenia 3
AU - Australia 3
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
BN - Brunei Darussalam 3
CR - Costa Rica 3
IL - Israele 3
KZ - Kazakistan 3
LI - Liechtenstein 3
NO - Norvegia 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
BF - Burkina Faso 2
Totale 30.132
Salva come PNG Salva come JPEG
Città #
Fairfield 1.862
Woodbridge 1.800
Ashburn 1.411
Singapore 1.381
Ann Arbor 1.043
Houston 1.020
Chandler 1.002
Seattle 768
Wilmington 737
Jacksonville 706
Hong Kong 696
San Jose 645
Cambridge 637
Beijing 579
Dearborn 463
Boardman 337
Council Bluffs 276
Lauterbourg 231
Princeton 230
Dublin 228
Los Angeles 228
Udine 228
Munich 226
Izmir 175
Ho Chi Minh City 165
Helsinki 157
Hefei 119
New York 114
Dallas 107
Hanoi 101
Buffalo 94
São Paulo 90
San Diego 88
Seoul 86
Redondo Beach 85
The Dalles 76
Ottawa 67
Santa Clara 55
Des Moines 54
Warsaw 48
Nuremberg 47
Mumbai 45
Brussels 40
Tokyo 39
Frankfurt am Main 38
Mexico City 38
Norwalk 35
Kunming 34
Ogden 34
Orem 33
Shanghai 31
Baghdad 30
Falls Church 30
Rio de Janeiro 30
Montreal 29
Nanjing 29
Denver 26
Phoenix 26
Atlanta 25
Chicago 25
Da Nang 25
Leawood 25
Toronto 25
Brooklyn 23
Guangzhou 23
San Francisco 23
Chennai 22
Johannesburg 22
Dong Ket 21
Stockholm 21
Vienna 21
Washington 19
Amsterdam 18
London 18
Tashkent 18
Trieste 18
Düsseldorf 17
San Mateo 17
Zanjan 16
Belo Horizonte 15
Chongqing 15
Dhaka 15
Jinan 15
Quito 15
Hangzhou 14
Manchester 14
Nairobi 14
Poplar 14
Zhengzhou 14
Augusta 13
Lahore 13
Milan 13
Rome 13
Turku 13
Ankara 12
Belluno 12
Guarulhos 12
Haiphong 12
Istanbul 12
Asunción 11
Totale 19.752
Salva come PNG Salva come JPEG
Nome #
Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C. 255
Deficient antithrombin III activity and enhanced fibrinolysis in patients with liver disease: Evidence against a cause-effect relationship 250
Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients. 239
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 235
Increase of Serum aú1-Acid Glycoprotein Despite the Decline of Liver Synthetic Function in Cirrhotics with Hepatocellular Carcinoma 233
A single-center experience of late retransplantation of the liver. 232
Steatosis of the graft is a risk factor for posttransplantation biliary complications. 230
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 224
Skills and requirements of a transplant hepatologist: board certification of the Italian Association for the Study of the Liver (AISF). 219
Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C 214
Association between the epidermal growth factor rs4444903 G/G genotype and advanced fibrosis at a young age in chronic hepatitis C. 209
LONG-TERM OUTCOMES OF ORTHOTOPIC LIVER TRANSPLANTATION IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS AND COMPARISON WITH HUMAN IMMUNODEFICIENCY VIRUS-NEGATIVE CASES 204
Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study 201
PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis 198
Apolipoprotein E genotypes modulate fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. 195
Management of infections in cirrhotic patients: report of a consensus conference. 194
Liver transplantation from old donors into HCV and non-HCV recipients 193
Early activation of interferon-stimulated genes in human liver allografts: relationship with acute rejection and histological outcome. 190
Intensity of inflammatory damage and serum lipid peroxide concentrations in liver disease 189
Toll Like Receptor 4 D299G Associates with Disease Progression in Caucasian Patients with Chronic HBV Infection: Relationship with Gender. 186
Association between vitamin D receptor genetic polymorphisms and acute cellular rejection in liver-transplanted patients. 183
A comparison of four serum markers of fibrosis in the diagnosis of cirrhosis 183
Clinical and virologic response to entecavir in HBV related chronic hepatitis or cirrhosis: data from the clinical practice in a single centre cohort. 181
The interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. 180
Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. 178
Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. 178
Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy 177
Serum soluble vascular-cell adhesion molecule-1 (VCAM-1) in patients with acute and chronic liver diseases 177
DE NOVO TUMORS ARE A MAJOR CAUSE OF LATE MORTALITY AFTER ORTHOTOPIC LIVER TRANSPLANTATION 175
Changes in blood lipid composition and response to interferon treatment in chronic hepatitis C 173
Degree of bile-duct dilatation in liver-transplanted patients with biliary stricture: a magnetic resonance cholangiography-based study. 172
Low fibrosis progression of recurrent hepatitis C in apolipoprotein E e4 carriers: relationship with the blood lipid profile 171
Biliary strictures after liver transplantation: Role of interleukin 28B genotypes in cyclosporine treated 170
Genetic polymorphisms of vitamin D pathway predict antiviral treatment outcome in slow responder naïve patients with chronic hepatitis C. 170
A study on role of the family and other risk factors in HCV transmission 168
Mild sialoadenitis: a common finding in patients with hepatitis C virus infection 167
Circulating intercellular adhesion molecule-1 (cICAM-1) concentration in liver disease. Relationship with cholestasis and functioning hepatic mass. 167
Expression of the interferon-inducible proteins MxA and IFI16 in liver allografts. 166
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial 166
Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. 165
STEATOSIS OF THE HEPATIC GRAFT AS A RISK FACTOR FOR POST-TRANSPLANT BILIARY COMPLICATIONS 165
INFLUENCE OF ANGIOTENSIN-CONVERTING ENZYME I/D GENE POLYMORPHISM ON CLINICAL AND HISTOLOGICAL CORRELATES OF CHRONIC HEPATITIS C 164
Specific issues concerning the management of patients on the waiting list and after liver transplantation 163
Splenic Artery Syndrome as a Possible Cause of Late Onset Refractory Ascites after Liver Transplantation: Management with Proximal Splenic Artery Embolization 162
Genetic polymorphisms of interleukin-6 modulate fibrosis progression in mild chronic hepatitis C 162
Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients 162
Quality-of-life assessment before and after liver transplantation. 161
Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. 160
Weight gain after liver transplantation and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene 160
GENE POLYMORPHISM AT THE INTERLEUKIN 6 -174 G > C LOCUS AFFECTS THE OUTCOME OF CHRONIC HEPATITIS B 160
Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation 158
Impact of magnetic resonance cholangiography in managing liver-transplanted patients: preliminary results of a clinical decision-making study 158
DIFFUSION-WEIGHTED MRI IN EVALUATING LIVER FIBROSIS: A FEASIBILITY STUDY IN CIRRHOTIC PATIENTS 157
Favourable Outcome of Adefovir-Dipivoxil Treatment in Acute de Novo Hepatitis B After Liver Transplantation 156
Acute alcoholic hepatitis and liver transplantation: Waiting for Godot 156
Consensus conference on TIPS management: Techniques, indications, contraindications 156
Safety and efficacy of splenic artery embolization for portal hyperperfusion in liver transplant recipients: A 5-year experience 156
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. 155
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 155
Anti-envelope antibodies in anti-hepatitis C virus (HCV) positive patients with and without liver disease 155
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. 155
Occult hepatitis B virus infection in peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. 155
Hepatic release of erythropoietin induced by transarterial chemoembolization in patients with hepatocellular carcinoma. 153
OCCULT HEPATITIS B VIRUS INFECTION IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HEPATITIS C: RELATIONSHIP WITH DONOR AGE AND FIBROSIS PROGRESSION 153
Prevalence and risk factors for delayed adrenal insufficiency after liver transplantation 151
Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases 151
Evidence for a multifactorial control of serum erythropoietin concentration in liver disease 150
Recipient interleukin-28B Rs12979860 C/T polymorphism and acute cellular rejection after liver transplantation: role of the calcineurin inhibitor used. 149
Vitamin A deficiency is associated with hepatitis C virus chronic infection and with unresponsiveness to interferon-based antiviral therapy. 149
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 149
Diagnostic usefulness of acute-phase protein measurement in hepatocellular carcinoma. 149
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial 149
Chronic sialoadenitis associated with HCV-related liver disease: differences in comparison to Sjogren syndrome 149
Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment 149
Recipient perioperative cholesterolaemia and graft cholesterol metabolism gene expression predict liver transplant outcome. 147
Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end stage liver disease 147
Vitamin D and the risk of acute allograft rejection following human liver transplantation. 146
Genetic polymorphisms of inflammatory cytokines and liver fibrosis progression due to recurrent hepatitis C. 145
HUMAN LEUKOCYTE ANTIGEN POLYMORPHISMS IN ITALIAN PRIMARY BILIARY CIRRHOSIS: A MULTICENTER STUDY OF 664 PATIENTS AND 1992 HEALTHY CONTROLS 145
Predictors of endoscopic treatment outcome in the management of biliary complications after orthotopic liver transplantation 145
Carriage of the EGF rs4444903 A>G functional polymorphism associates with disease progression in chronic HBV infection. 145
Impact of apolipoprotein E genetic polymorphisms on liver disease: An essential review 145
IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. 145
Factors associated with serum HCV RNA positivity in anti HCV antibody positive intravenous drug users 143
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. 143
Sex-related influence of angiotensin-converting enzyme polymorphisms on fibrosis progression due to recurrent hepatitis C after liver transplantation 142
Non-specific increase of serum carbohydrate antigen 19-9 in patients with liver disease associated with increased circulating levels of adhesion molecules. 142
IgM antibody response to the hepatitis C virus core protein in intravenous drug users. 141
Hepatitis B virus and lymphomagenesis: novel insights into an occult relationship. 140
Antiviral treatment of hepatitis C 140
Value of serum C-reactive protein measurement in the detection of hepatocellular carcinoma superimposed on liver cirrhosis 139
Genetic polymorphism at the apolipoprotein E locus affects the outcome of chronic hepatitis B 139
Reliability and reproducibility of the Edmonson grading of hepatocellular carcinoma using paired core biopsy and surgical resection specimens 139
Successful minimally invasive management of late portal vein thrombosis after splenectomy due to splenic artery steal syndrome following liver transplantation: a case report 139
SERUM FERRITIN AS A PREDICTOR OF TREATMENT OUTCOME IN PATIENTS WITH CHRONIC HEPATITIS C 138
Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation 136
A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a "blended Principle Model" 136
Antiviral treatment in patients with hepatitis C virus related cirrhosis awaiting liver transplantation 135
Increased serum phospholipase A2 activity in advanced chronic liver disease as an expression of the acute phase response. 135
Steatosis of the hepatic graft as a risk factor for post-transplant biliary complications 134
Totale 16.720
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.331
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.331
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021169 0 0 0 0 0 0 0 0 0 0 0 169
2021/20221.861 81 149 112 110 27 104 108 97 32 278 479 284
2022/20232.254 259 167 35 304 229 580 1 174 339 25 79 62
2023/2024674 132 78 32 18 138 97 15 33 58 38 10 25
2024/20254.680 100 289 145 172 141 311 304 339 570 361 743 1.205
2025/20268.320 645 923 733 710 1.328 688 945 307 591 730 576 144
Totale 30.707